Leap Therapeutics, Inc.
LPTX
$0.369
-$0.0053-1.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.48% | -12.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.14% | -12.60% | |||
| Operating Income | 12.14% | 12.60% | |||
| Income Before Tax | 10.96% | 14.21% | |||
| Income Tax Expenses | -117.37% | -- | |||
| Earnings from Continuing Operations | 15.10% | 10.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.10% | 10.74% | |||
| EBIT | 12.14% | 12.60% | |||
| EBITDA | 12.14% | 12.60% | |||
| EPS Basic | 13.92% | 15.25% | |||
| Normalized Basic EPS | -77.88% | 17.63% | |||
| EPS Diluted | 13.92% | 15.25% | |||
| Normalized Diluted EPS | -77.88% | 17.63% | |||
| Average Basic Shares Outstanding | 0.10% | 5.33% | |||
| Average Diluted Shares Outstanding | 0.10% | 5.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||